TRVI

6.29

3.23% -0.21

After Hours: 6.29

Trevi Therapeutics Inc (TRVI)

Overview News Price History Option Chain Financials Discussions Forecast

Trevi Therapeutics Inc stock is traded at $6.29, with a volume of 2.56M. It is down -3.23% in the last 24 hours and up +39.16% over the past month.

Previous Close:

$6.50

Open:

$6.25

24h Volume:

2.56M

Relative Volume:

1.42

Market Cap:

$618.77M

Revenue:

Net Income/Loss:

$-29.07M

P/E Ratio:

-21.69

EPS:

-0.29

Net Cash Flow:

$-31.85M

1W Performance:

-1.72%

1M Performance:

+39.16%

6M Performance:

+88.32%

1Y Performance:

+82.32%

1-Day Range:

$6.10

$6.50

1-Week Range:

$6.10

$6.785

52-Week Range:

$2.30

$7.39

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name

Trevi Therapeutics Inc

Sector

Healthcare (1164)

Industry

Biotechnology (681)

Phone

203-304-2499

Address

195 CHURCH STREET, NEW HAVEN, CT

Employee

Twitter

@TreviThera

Next Earnings Date

2025-03-18

Latest SEC Filings

TRVI's Discussions on Twitter

Compare TRVI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRVI Trevi Therapeutics Inc	6.29	618.77M	0	-29.07M	-31.85M	-0.29
VRTX Vertex Pharmaceuticals Inc	484.82	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	634.23	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	591.87	36.10B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	270.02	35.03B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	272.17	28.24B	3.81B	-644.79M	-669.77M	-6.24

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-10-25	Reiterated	Needham	Buy
Mar-10-25	Upgrade	Raymond James	Outperform → Strong Buy
Dec-12-24	Reiterated	H.C. Wainwright	Buy
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-30-24	Initiated	H.C. Wainwright	Buy
Aug-30-24	Initiated	Raymond James	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-12-23	Initiated	B. Riley Securities	Buy
Nov-22-22	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	BMO Capital Markets	Outperform
Jun-03-19	Initiated	Needham	Buy
Jun-03-19	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	Stifel	Buy

View All

Trevi Therapeutics Inc Stock (TRVI) Latest News

11:35 AM

Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones - Proactive financial news

11:35 AM

Mar 28, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Bank of New York Mellon Corp - Defense World

Mar 28, 2025

Mar 26, 2025

Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock - Investing.com

Mar 26, 2025

Mar 25, 2025

Trevi therapeutics CEO Jennifer Good sells $34,624 in stock By Investing.com - Investing.com South Africa

Mar 25, 2025

Trevi therapeutics CEO Jennifer Good sells $34,624 in stock - Investing.com

Mar 25, 2025

Mar 22, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 22, 2025

HC Wainwright Reiterates “Buy” Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World

Mar 21, 2025

Trevi Therapeutics (NASDAQ:TRVI) Earns “Buy” Rating from B. Riley - Defense World

Mar 21, 2025

D. Boral Capital Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World

Mar 21, 2025

Needham & Company LLC Lowers Trevi Therapeutics (NASDAQ:TRVI) Price Target to $24.00 - Defense World

Mar 21, 2025

Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Price Target at $15.94 - Defense World

Mar 21, 2025

Mar 20, 2025

Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up Following Better-Than-Expected Earnings - Defense World

Mar 20, 2025

Trevi Therapeutics Stock (TRVI) Surges Over 60% on Promising Trial Results and Q4 Financials - Markets Insider

Mar 20, 2025

Mar 19, 2025

B. Riley Boosts Price Target on Trevi Therapeutics to $20 From $11, Keeps Buy Rating - Marketscreener.com

Mar 19, 2025